1. Academic Validation
  2. Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma

Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma

  • Cancer Cell. 2020 May 11;37(5):674-689.e12. doi: 10.1016/j.ccell.2020.03.016.
Elie Dheilly 1 Elena Battistello 2 Natalya Katanayeva 1 Stephanie Sungalee 1 Justine Michaux 3 Gerben Duns 4 Sarah Wehrle 5 Jessica Sordet-Dessimoz 6 Marco Mina 7 Julien Racle 8 Pedro Farinha 4 George Coukos 3 David Gfeller 8 Anja Mottok 9 Robert Kridel 10 Bruno E Correia 11 Christian Steidl 4 Michal Bassani-Sternberg 3 Giovanni Ciriello 7 Vincent Zoete 12 Elisa Oricchio 13
Affiliations

Affiliations

  • 1 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, 1015 Switzerland; Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland.
  • 2 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, 1015 Switzerland; Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Department of Computational Biology, University of Lausanne, 1015 Lausanne, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland.
  • 3 Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne, Switzerland; Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.
  • 4 Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada.
  • 5 Institute of Bioengineering, EPFL, 1015 Lausanne, Switzerland.
  • 6 Histology Core Facility, EPFL, 1015 Lausanne, Switzerland.
  • 7 Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Department of Computational Biology, University of Lausanne, 1015 Lausanne, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland.
  • 8 Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland; Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne, Switzerland; Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.
  • 9 Institute of Human Genetics, Ulm University and Ulm University Medical Center, Germany.
  • 10 Princess Margaret Cancer Center, Toronto, Canada.
  • 11 Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland; Institute of Bioengineering, EPFL, 1015 Lausanne, Switzerland.
  • 12 Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland; Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne, Switzerland; Molecular Modeling Group, SIB, Lausanne, Switzerland.
  • 13 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, 1015 Switzerland; Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland. Electronic address: elisa.oricchio@epfl.ch.
Abstract

Genomic alterations in Cancer cells can influence the immune system to favor tumor growth. In non-Hodgkin lymphoma, physiological interactions between B cells and the germinal center microenvironment are coopted to sustain Cancer cell proliferation. We found that follicular lymphoma patients harbor a recurrent hotspot mutation targeting tyrosine 132 (Y132D) in Cathepsin S (CTSS) that enhances protein activity. CTSS regulates antigen processing and CD4+ and CD8+ T cell-mediated immune responses. Loss of CTSS activity reduces lymphoma growth by limiting communication with CD4+ T follicular helper cells while inducing antigen diversification and activation of CD8+ T cells. Overall, our results suggest that CTSS inhibition has non-redundant therapeutic potential to enhance anti-tumor immune responses in indolent and aggressive lymphomas.

Keywords

T cells; antigen presentation; cysteine proteases; germinal centers; immunotherapy; lymphoma.

Figures
Products